Company: FENC
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001558370-25-007748
Chunk: 9

Company: FENNEC PHARMACEUTICALS INC.
Filing Date: 2025-05-14
Form: 10-Q
Item: Part II, Item 3D
Chunk 9
---
Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

Insider Trading Arrangements and Policies

During the quarter ended March 31, 2025, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulations S-K.

​

Press Release

On May 13, 2025, we issued a press release announcing our financial results for the quarter ended March 31, 2025. A copy of the news release is attached to this Quarterly Report as Exhibit 99.1. The press release is being furnished and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, unless such subsequent filing specifically references the press release.

​

Item 6. Exhibits

​

ExhibitNo.    Description​​​31.1​Certification of Chief Executive Officer of the Company in accordance with Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith). ​ 31.2​Certification of Chief Financial Officer of the Company in accordance with Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith). ​ 32.1​Certification of Chief Executive Officer and Chief Financial Officer of the Company in accordance with Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith). ​ 99.1​Press Release for Quarter Ended March 31, 2024 (filed herewith).